Eosinophilic Esophagitis - 8 Studies Found
| NOT_YET_RECRUITING |
: Validation in French of a Quality of Life Questionnaire for Patients With Eosinophilic Esophagitis in Pediatrics : : 2025-11-04 : Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module |
| Completed |
: A Study to Investigate Safety and Tolerability of NDX-3315 in Healthy Participants and Patients With Eosinophilic Esophagitis : Eosinophilic Esophagitis : 2025-11-04 : Oral solution |
| Completed |
: Zemaira Eosinophilic Esophagitis Pilot Study : Eosinophilic Esophagitis : 2025-11-04 : Intravenous infusion at 120 mg/kg body weight dose/week for 12 weeks for a total of 12 infusions. |
| Completed |
: Imaging of the Esophagus Using a SECM Capsule : Eosinophilic Esophagitis : 2025-11-04 : Subjects will swallow a SECM capsule and the SECM imaging will be performed |
| Completed |
: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis : Eosinophilic Esophagitis : 2025-11-04 : subcutaneous administration |
| COMPLETED |
: Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis : Eosinophilic Esophagitis : 2025-11-04 : 1-hour intravenous infusion |
| COMPLETED |
: 24-Week Induction Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis (EoE) (FLUTE 3) : Eosinophilic Esophagitis : 2025-11-04 : APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.Other Names:fluticasone pro |
| COMPLETED |
: Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation : Eosinophilic Esophagitis : 2025-11-04 : AQ280 administered orally in capsule formulation. |